Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia

Published:2017-05-30 Issue:2 Volume:117 Page:256-265
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Forero-Castro Maribel,Robledo Cristina,Benito Rocío,Bodega-Mayor Irene,Rapado Inmaculada,Hernández-Sánchez María,Abáigar María,Maria Hernández-Sánchez Jesús,Quijada-Álamo Miguel,María Sánchez-Pina José,Sala-Valdés Mónica,Araujo-Silva Fernanda,Kohlmann Alexander,Luis Fuster José,Arefi Maryam,de las Heras Natalia,Riesco Susana,Rodríguez Juan N,Hermosín Lourdes,Ribera Jordi,Camos Guijosa Mireia,Ramírez Manuel,de Heredia Rubio Cristina Díaz,Barragán Eva,Martínez Joaquín,Ribera José M,Fernández-Ruiz Elena,Hernández-Rivas Jesús-María

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017152.pdf

Reference57 articles.

1. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372 (9648): 1484–1492.

2. Bhojwani D, Yang JJ, Pui CH (2015) Biology of childhood acute lymphoblastic leukaemia. Pediatr Clin North Am 62 (1): 47–60.

3. Bungaro S, Dell'Orto MC, Zangrando A, Basso D, Gorletta T, Lo Nigro L, Leszl A, Young BD, Basso G, Bicciato S, Biondi A, te Kronnie G, Cazzaniga G (2009) Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes Cancer 48 (1): 22–38.

4. Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NJ, Hunger SP, Willman CL (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 119 (15): 3512–3522.

5. Chiaretti S, Brugnoletti F, Messina M, Paoloni F, Fedullo AL, Piciocchi A, Elia L, Vitale A, Mauro E, Ferrara F, De Fabritiis P, Luppi M, Ronco F, De Propris MS, Raponi S, Kronnie GT, Vignetti M, Guarini A, Foa R (2016) CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leuk Res 41: 36–42.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low‐dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe‐BIRD) in a child with relapsed/refractory B‐cell acute lymphoblastic leukemia with TP53 mutation;Pediatric Blood & Cancer;2024-07-02

2. Advances in next-generation sequencing for relapsed pediatric acute lymphoblastic leukemia: current insights and future directions;Frontiers in Genetics;2024-06-04

3. TP53 deletion as an MRD-dependent risk factor in childhood B-ALL: a post hoc analysis from a prospective cohort;2024-05-09

4. Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia;Annals of Hematology;2024-03-07

5. Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen;Leukemia & Lymphoma;2023-11-08